Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Hiroki Tsuchihashi"'
Autor:
Kohei Okuyama, Keiji Suzuki, Tomofumi Naruse, Hiroki Tsuchihashi, Souichi Yanamoto, Atsushi Kaida, Masahiko Miura, Masahiro Umeda, Shunichi Yamashita
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is an efficient anti-tumor therapeutic agent that inhibits the activation of EGFR; however, data related to the cellular effects of prolonged cetuximab treatment
Externí odkaz:
https://doaj.org/article/e696f56cecc94299aeb6208f2e259997
Autor:
Tomofumi Naruse, Kohei Furukawa, Masahiro Umeda, Keisuke Omori, Hiroki Tsuchihashi, Souichi Yanamoto
Publikováno v:
Journal of Japanese Society of Oral Oncology. 33:119-125
Autor:
Kazuki Mori, Tomofumi Hamada, Mahiro Beppu, Hiroki Tsuchihashi, Yuichi Goto, Kenichi Kume, Hiroshi Hijioka, Keitaro Nishi, Yumiko Mishima, Tsuyoshi Sugiura
Publikováno v:
Cancers; Volume 14; Issue 11; Pages: 2646
Clinically, early-stage oral cancers are difficult to distinguish from oral potentially malignant disorders (OPMDs), and invasive tissue biopsy should be performed to determine a treatment strategy. Previously, we focused on gargle fluid as a noninva
Autor:
Hiroki Tsuchihashi, Keisuke Omori, Kohei Furukawa, Masahiro Umeda, Souichi Yanamoto, Kohei Okuyama, Tomofumi Naruse
Publikováno v:
Oncology Reports
High expression of the 110 kDa catalytic subunit of the class IA PI3K (PI3Kp110α) may play an important role in cetuximab resistance exhibited by both colorectal cancer and head and neck squamous cell carcinoma. Therefore, the present study aimed to
Autor:
Masahiro Umeda, Kohei Okuyama, Tomofumi Naruse, Kohei Furukawa, Hiroki Tsuchihashi, Souichi Yanamoto
Publikováno v:
Japanese Journal of Oral Diagnosis / Oral Medicine. 33:153-159
Autor:
Masahiko Miura, Atsushi Kaida, Hiroki Tsuchihashi, Souichi Yanamoto, Kohei Okuyama, Keiji Suzuki, Tomofumi Naruse, Masahiro Umeda, Shunichi Yamashita
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is an efficient anti-tumor therapeutic agent that inhibits the activation of EGFR; however, data related to the cellular effects of prolonged cetuximab treatment are limi
Autor:
Hiroki Tsuchihashi, Hiromasa Fukushima, Masahiro Umeda, Tomofumi Naruse, Kohei Okuyama, Souichi Yanamoto
Publikováno v:
Pathology & Oncology Research. 25:603-609
Oral squamous cell carcinoma (OSCC) with invasion into the mandibular medullary space has been reported to be a predictive factor for cervical lymph node metastasis (CLNM). As CLNM has been associated with the stemness of cancer cells, we aimed to ev
Autor:
Yuki Sakamoto, Souichi Yanamoto, Hiroki Tsuchihashi, Masahiro Umeda, Mitsuko Tokuhisa, Tomofumi Naruse, Kohei Okuyama
Publikováno v:
Oncology Letters
Long-term cetuximab treatment can lead to acquired resistance, and tumor progression and/or new lesions often occur. The present report describes a case of lower gingival squamous cell carcinoma with brain metastasis during long-term cetuximab treatm
Autor:
Hiroki Tsuchihashi, Keisuke Omori, Kohei Okuyama, Tomofumi Naruse, Shuichi Fujita, Masahiro Umeda, Souichi Yanamoto, Akiko Kawakita, Yuki Sakamoto
Publikováno v:
Molecular and Clinical Oncology
Spindle cell carcinoma (SpCC), which predominantly arises in the oral, pharyngeal and laryngeal mucosal tissues, is composed of a mixture of squamous and sarcomatoid components. The present study describes the case of a 62-year-old woman with SpCC re
Autor:
Hiroki Tsuchihashi, Keisuke Ohmori, Kohei Okuyama, Masahiro Umeda, Souichi Yanamoto, Kohei Furukawa, Shin-ichi Yamada, Tomofumi Naruse
Publikováno v:
Pathology oncology research : POR. 26(2)
While neoadjuvant chemotherapy (NAC) for patients with oral tongue squamous cell carcinoma (OTSCC) may improve tumor microenvironment, it may lead to local immune suppression caused by residual cancer cells. The efficacy of NAC is therefore controver